Activaero GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Activaero GmbH - overview
Established
1998
Location
-, -, Germany
Primary Industry
Medical Devices & Equipment
About
Activaero GmbH, based in Germany, specializes in innovative aerosol delivery technologies for pharmaceutical applications, enhancing drug delivery systems for improved patient outcomes. Founded in 1998, Activaero GmbH operates in the healthcare sector, focusing on aerosol technology for respiratory and other medical applications. The company has undergone changes in its strategic direction to enhance its product offerings and market presence. Activaero has received significant investment, notably a TRADE SALE of EUR 130.
000 mn from Vectura Group Plc on March 21, 2014, which addressed its funding needs. The company has completed a total of 4 deals to date. Activaero GmbH specializes in aerosol delivery systems designed to improve the effectiveness of pharmaceutical treatments, particularly for respiratory conditions. Their products aim to ensure precise drug administration to enhance patient outcomes.
Activaero's technology is utilized in various applications, making it an important player in the global healthcare technology market, particularly in Europe and North America. Activaero generates revenue through the sale of its aerosol delivery devices and related technology to healthcare providers and pharmaceutical companies. The revenue model includes direct sales to hospitals and clinics, as well as partnerships with other companies that integrate Activaero's technology into their product offerings. This strategy allows for flexible pricing structures based on demand and usage.
Activaero aims to expand its product lineup with the introduction of next-generation aerosol devices expected to launch in late 2024. The company is also targeting market expansion into Asia by 2025, focusing on countries with growing healthcare needs. The recent TRADE SALE funding will be utilized to support research and development for new products and to establish partnerships in the Asian market.
Current Investors
BioMed Partners, Vesalius Biocapital, Vi Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Medical Devices & Equipment
Website
www.activaero.de
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Activaero GmbH - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.